Terms: = Skin cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
205 results:
1. Identification of prognostic m6A modification patterns and score system in melanoma patients.
Wang F; Chen P; Ouyang S; Xiong K; Liu Z; Wang Y
Medicine (Baltimore); 2024 Apr; 103(17):e37950. PubMed ID: 38669381
[TBL] [Abstract] [Full Text] [Related]
2. Differential Upregulation of Th1/Th17-Associated Proteins and pd-l1 in Granulomatous Mycosis Fungoides.
Marques-Piubelli ML; Navarrete J; Ledesma DA; Hudgens CW; Lazcano RN; Alani A; Huen A; Duvic M; Nagarajan P; Aung PP; Wistuba II; Curry JL; Miranda RN; Torres-Cabala CA
Cells; 2024 Feb; 13(5):. PubMed ID: 38474383
[TBL] [Abstract] [Full Text] [Related]
3. Effects of immunogenic cell death-inducing chemotherapeutics on the immune cell activation and tertiary lymphoid structure formation in melanoma.
Zhao H; Zhao Y; Zhang S; Wang Z; Yu W; Dong N; Yang X; Zhang X; Sun Q; Hao X; Ren X
Front Immunol; 2024; 15():1302751. PubMed ID: 38384466
[TBL] [Abstract] [Full Text] [Related]
4. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.
Eriksen PRG; de Groot F; Clasen-Linde E; de Nully Brown P; de Groen R; Melchior LC; Maier AD; Minderman M; Vermaat JSP; von Buchwald C; Pals ST; Heegaard S
Blood Adv; 2024 Apr; 8(8):1946-1957. PubMed ID: 38324724
[TBL] [Abstract] [Full Text] [Related]
5. Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints.
Cannon AC; Budagyan K; Uribe-Alvarez C; Kurimchak AM; Araiza-Olivera D; Cai KQ; Peri S; Zhou Y; Duncan JS; Chernoff J
Oncogene; 2024 Mar; 43(10):729-743. PubMed ID: 38243078
[TBL] [Abstract] [Full Text] [Related]
6. TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy.
Wang S; Xiong Y; Zhang Y; Wang H; Chen M; Li J; Luo P; Luo YH; Hecht M; Frey B; Gaipl U; Li X; Zhao Q; Ma H; Zhou JG
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212124
[TBL] [Abstract] [Full Text] [Related]
7. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
8. The molecular subtypes and clinical prognosis characteristic of tertiary lymphoid structures-related gene of cutaneous melanoma.
Li J; Chen G; Luo Y; Xu J; He J
Sci Rep; 2023 Dec; 13(1):23097. PubMed ID: 38155221
[TBL] [Abstract] [Full Text] [Related]
9.
Xie Y; Li Y; Yang M
J Immunol Res; 2023; 2023():5041223. PubMed ID: 38125697
[No Abstract] [Full Text] [Related]
10. pd-l1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast cancers and Its Clinicopathological Significance.
Han EK; Woo JW; Suh KJ; Kim SH; Kim JH; Park SY
Cancer Res Treat; 2024 Apr; 56(2):557-566. PubMed ID: 38097920
[TBL] [Abstract] [Full Text] [Related]
11. Association between immune-related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis.
Euvrard R; Robert M; Mainbourg S; Dalle S; Lega JC
Fundam Clin Pharmacol; 2024 Apr; 38(2):369-379. PubMed ID: 38012082
[TBL] [Abstract] [Full Text] [Related]
12. Mechanisms and biomarkers of immune-related adverse events in gastric cancer.
Ding P; Liu P; Meng L; Zhao Q
Eur J Med Res; 2023 Nov; 28(1):492. PubMed ID: 37936161
[TBL] [Abstract] [Full Text] [Related]
13. Penile melanoma: a pathological report of two cases.
Pósfai B; Szentkereszty M; Sánta F; Bajory Z; Simon A; Kozéki Z; Csányi I; Akgul M; Kuthi L
Diagn Pathol; 2023 Oct; 18(1):117. PubMed ID: 37898793
[TBL] [Abstract] [Full Text] [Related]
14. Construction of a novel prognostic model in skin cutaneous melanoma based on chemokines-related gene signature.
Ding X; Wang W; Tao X; Li Z; Huang Y
Sci Rep; 2023 Oct; 13(1):18172. PubMed ID: 37875556
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathologic Evaluation of CD80, CD86, and pd-l1 Expressions with Immunohistochemical Methods in Malignant Melanoma Patients.
Cobankent Aytekin E; Unal B; Bassorgun CI; Ozkan O
Turk Patoloji Derg; 2024; 40(1):16-26. PubMed ID: 37614091
[TBL] [Abstract] [Full Text] [Related]
16. CD3ζ as a novel predictive biomarker of PD-1 inhibitor resistance in melanoma.
Zhang Z; Zhang D; Wang F; Liu J; Jiang X; Anuchapreeda S; Tima S; Xiao Z; Duangmano S
Mol Cell Probes; 2023 Dec; 72():101925. PubMed ID: 37567322
[TBL] [Abstract] [Full Text] [Related]
17. ANXA1 Promotes Tumor Immune Evasion by Binding PARP1 and Upregulating Stat3-Induced Expression of pd-l1 in Multiple cancers.
Xiao D; Zeng T; Zhu W; Yu ZZ; Huang W; Yi H; Lu SS; Feng J; Feng XP; Wu D; Wen Q; Zhou JH; Yuan L; Zhuang W; Xiao ZQ
Cancer Immunol Res; 2023 Oct; 11(10):1367-1383. PubMed ID: 37566399
[TBL] [Abstract] [Full Text] [Related]
18. SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.
An F; Zhang W; Guo Y; Shi F; Kong Y; Tang L; Han C; Wang Q
Aging (Albany NY); 2023 Aug; 15(15):7476-7495. PubMed ID: 37535001
[TBL] [Abstract] [Full Text] [Related]
19. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Ascierto PA; Agarwala SS; Warner AB; Ernstoff MS; Fox BA; Gajewski TF; Galon J; Garbe C; Gastman BR; Gershenwald JE; Kalinski P; Krogsgaard M; Leidner RS; Lo RS; Menzies AM; Michielin O; Poulikakos PI; Weber JS; Caracò C; Osman I; Puzanov I; Thurin M
J Transl Med; 2023 Jul; 21(1):508. PubMed ID: 37507765
[TBL] [Abstract] [Full Text] [Related]
20. Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.
Teng YS; Yu S
Curr Oncol; 2023 Jul; 30(7):6805-6819. PubMed ID: 37504358
[TBL] [Abstract] [Full Text] [Related]
[Next]
